肿瘤细胞治疗研究
英文原题:CCR2/CXCR6 enhances tumor infiltration and antitumor efficacy of MSLN CAR-T cells.
CCR2/CXCR6 enhances tumor infiltration and antitumor efficacy of MSLN CAR-T cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR-T(CAR-T)细胞疗法在治疗实体瘤方面显示出前景,但临床成功往往受限于肿瘤浸润不足。在本研究中,我们试图构建两种靶向MSLN的CAR-T 细胞变体,Intra2和Intra6,分别表达CCR2和CXCR6,以改善其向肿瘤微环境的迁移。流式细胞术证实了受体的稳定表达。体外实验表明,与常规MSLN CAR-T 细胞相比,Intra2和Intra6 CAR-T 细胞均表现出显著改善的功能表型、迁移和侵袭能力,以及持续杀伤靶细胞的能力。值得注意的是,在体内,Intra6 CAR-T 细胞显示出更优的抗肿瘤效果,表现为增强的肿瘤抑制和减少的耗竭。RNA测序分析显示,CXCR6表达上调了与免疫激活、迁移、黏附和细胞骨架重塑相关的基因,如LFA-1、PAK1和FSCN1,提示迁移和跨内皮浸润能力改善。RT-qPCR和流式细胞术证实了Intra6 CAR-T 细胞中LFA-1表达更高且迁移能力增强。重要的是,LFA-1对CXCR6驱动的迁移至关重要。这些结果表明,对靶向MSLN的CAR-T 细胞进行趋化因子受体修饰可显著改善其肿瘤浸润和治疗疗效,为优化针对表达mesothelin的癌症的CAR-T 细胞疗法提供了潜在策略。方法:我们通过分别引入趋化因子受体CCR2和CXCR6,构建了两种CAR-T 细胞变体,Intra2和Intra6。这些修饰细胞的迁移和肿瘤浸润能力通过体外迁移实验和体内荷瘤小鼠模型进行了评估。通过流式细胞术分析了CAR-T 细胞的表型特征,包括记忆T细胞亚群(干细胞记忆和中央记忆)。评估了肿瘤生长抑制情况,并对免疫耗竭和免疫逃逸标志物进行了定量检测。
Chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating solid tumors, but the clinical success is often limited by insufficient tumor infiltration. In this study, we sought to engineered two MSLN-targeted CAR-T cell variants, Intra2 and Intra6, expressing CCR2 and CXCR6, respectively, to improve their migration toward the tumor microenvironment. Flow cytometry confirmed stable receptor expression. In vitro assays demonstrated that both Intra2 and Intra6 CAR-T cells exhibited significantly improved functional phenotype, migration and invasion, as well as persistence in killing target cells compared to conventional MSLN CAR-T cells. Notably, in vivo, Intra6 CAR-T cells displayed superior antitumor effects, showing enhanced tumor suppression and reduced exhaustion. RNA sequencing analysis revealed that CXCR6 expression upregulated genes related to immune activation, migration, adhesion, and cytoskeletal remodeling, such as LFA-1, PAK1, and FSCN1, suggesting improved migration and transendothelial infiltration. RT-qPCR and flow cytometry confirmed higher LFA-1 expression and enhanced migratory capacity in Intra6 CAR-T cells. Importantly, LFA-1 was crucial for CXCR6-driven migration. These results suggest that chemokine receptor modification of MSLN-targeted CAR-T cells can significantly improve their tumor infiltration and therapeutic efficacy, offering a potential strategy to optimize CAR-T cell therapy for mesothelin-expressing cancers. METHODS: We engineered two CAR-T cell variants, Intra2 and Intra6, by introducing chemokine receptors CCR2 and CXCR6, respectively. The migration and tumor infiltration capabilities of these modified cells were evaluated in vitro through migration assays and in vivo using tumor-bearing mouse models. The phenotypic characteristics of the CAR-T cells, including memory T cell subsets (stem cell memory and central memory), were analyzed by flow cytometry. Tumor growth inhibition was assessed, and markers of immune exhaustion and evasion were quantified.
MEMBER ACCOUNT
登录成功会直接打开下一页。